← Leaderboards
Ie-Ming Shih
Johns Hopkins University
$14,895,140
Attributed
$19,652,353
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,314,690 · 15
By mechanism
P50$18,978,919 · 5
R01$11,781,813 · 5
U2C$3,094,498 · 1
U01$2,882,241 · 1
R33$1,038,932 · 1
R21$538,287 · 2
Top collaborators
- Zhen Zhang10 shared
- Thomas Russell Pisanic Ii5 shared
- James H. Segars5 shared
- Tian-Li Wang5 shared
- Tza-Huei Jeff Wang5 shared
- Ronny I Drapkin2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Cornelia L Trimble$7,319,162
- Amanda Nickles Fader$1,935,907
- Tian-Li Wang$3,014,402
- Charles W. Flexner$41,000,447
- Tza-Huei Jeff Wang$29,391,444
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryMalignant NeoplasmsWomanOvarianTumorBaseSpecimenTissuesFutureResearch PersonnelSerousCancer PatientNeoplastic CellPathologyMolecularCarcinomaOperative Surgical ProceduresResistancePathway InteractionsCancer CellEnsureGenesPathogenesisDiagnosis
Grant awards (65)
SPORE in Ovarian Cancer$2,402,856
P50 · FY2025 · CA · contact PI
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach$598,864
U2C · FY2025 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$417,626
R01 · FY2025 · CA
Administrative Core$300,358
P50 · FY2025 · CA · contact PI
Career Enhancement Program$300,357
P50 · FY2025 · CA · contact PI
SPORE in Ovarian Cancer$2,496,726
P50 · FY2024 · CA · contact PI
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach$892,664
U2C · FY2024 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$406,959
R01 · FY2024 · CA
Administrative Core$204,230
P50 · FY2024 · CA · contact PI
Career Enhancement Program$125,953
P50 · FY2024 · CA · contact PI
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach$923,097
U2C · FY2023 · CA
Role of cancer-associated mutations in endometriosis$660,893
R01 · FY2023 · HD
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$423,593
R01 · FY2023 · CA
SPORE in Ovarian Cancer$1,589,106
P50 · FY2022 · CA · contact PI
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach$679,873
U2C · FY2022 · CA
Role of cancer-associated mutations in endometriosis$669,600
R01 · FY2022 · HD
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$433,937
R01 · FY2022 · CA
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"$303,432
P50 · FY2022 · CA · contact PI
Admin Core$156,962
P50 · FY2022 · CA · contact PI
SPORE in Ovarian Cancer$2,304,828
P50 · FY2021 · CA · contact PI
Role of cancer-associated mutations in endometriosis$674,852
R01 · FY2021 · HD
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$443,815
R01 · FY2021 · CA
Experimental Therapeutics by targeting Spleen Tyrosine Kinase$375,163
R01 · FY2021 · CA · contact PI
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$309,067
U01 · FY2021 · CA
Admin Core$256,093
P50 · FY2021 · CA · contact PI
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"$256,091
P50 · FY2021 · CA · contact PI
SPORE in Ovarian Cancer$1,976,958
P50 · FY2020 · CA · contact PI
Role of cancer-associated mutations in endometriosis$698,200
R01 · FY2020 · HD
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$534,604
U01 · FY2020 · CA
Experimental Therapeutics by targeting Spleen Tyrosine Kinase$375,163
R01 · FY2020 · CA · contact PI
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"$307,924
P50 · FY2020 · CA · contact PI
Admin Core$153,038
P50 · FY2020 · CA · contact PI
SPORE in Ovarian Cancer$2,304,828
P50 · FY2019 · CA · contact PI
Role of cancer-associated mutations in endometriosis$739,745
R01 · FY2019 · HD
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$692,310
U01 · FY2019 · CA
Experimental Therapeutics by targeting Spleen Tyrosine Kinase$363,907
R01 · FY2019 · CA · contact PI
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"$336,182
P50 · FY2019 · CA · contact PI
Admin Core$175,838
P50 · FY2019 · CA · contact PI
SPORE in Ovarian Cancer$2,492,537
P50 · FY2018 · CA · contact PI
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$441,524
U01 · FY2018 · CA
Experimental Therapeutics by targeting Spleen Tyrosine Kinase$374,971
R01 · FY2018 · CA · contact PI
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"$345,550
P50 · FY2018 · CA · contact PI
Admin Core$189,072
P50 · FY2018 · CA · contact PI
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$441,524
U01 · FY2017 · CA
Experimental Therapeutics by targeting Spleen Tyrosine Kinase$374,208
R01 · FY2017 · CA · contact PI
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer$463,212
U01 · FY2016 · CA
Tumor Suppressor Role of ARID1A$198,725
R21 · FY2013 · CA · contact PI
The Roles of HBXAP Gene in Ovarian Cancer$330,091
R01 · FY2012 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$328,003
R01 · FY2012 · CA · contact PI
Tumor Suppressor Role of ARID1A$176,175
R21 · FY2012 · CA · contact PI
The Roles of HBXAP Gene in Ovarian Cancer$330,091
R01 · FY2011 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$328,003
R01 · FY2011 · CA · contact PI
The Roles of HBXAP Gene in Ovarian Cancer$340,300
R01 · FY2010 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$338,148
R01 · FY2010 · CA · contact PI
The Roles of HBXAP Gene in Ovarian Cancer$340,300
R01 · FY2009 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$338,148
R01 · FY2009 · CA · contact PI
The Roles of HBXAP Gene in Ovarian Cancer$340,300
R01 · FY2008 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$338,148
R01 · FY2008 · CA · contact PI
Molecular Diagnostics for Malignant Effusion$327,299
R01 · FY2006 · CA · contact PI
Development of Digital SNP Analysis in Cancer Detection$352,086
R33 · FY2005 · CA
Molecular Diagnostics for Malignant Effusion$335,175
R01 · FY2005 · CA
Development of Digital SNP Analysis in Cancer Detection$348,652
R33 · FY2004 · CA
Molecular Diagnostics for Malignant Effusion$335,175
R01 · FY2004 · CA
Development of Digital SNP Analysis in Cancer Detection$338,194
R33 · FY2003 · CA
Development of Digital SNP Analysis in Cancer Detection$163,387
R21 · FY2002 · CA